

CHART II

Supplier	Product name	Form	Application date
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 5 mg.	Glass ampule: 5 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 0.5 mg.	Glass ampule: 0.5 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 1 mg.	Glass ampule: 1 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 10 mg.	Glass ampule: 10 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 5 mg .....	Glass ampule: 5 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 0.5 mg .....	Glass ampule: 0.5 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 1 mg .....	Glass ampule: 1 mg .....	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 10 mg .....	Glass ampule: 10 mg .....	2/19/2021
Cayman Chemical Company .....	Clonazepam (CRM) 1 mg/mL, 1 mL in acetonitrile .....	Glass ampule: 1 mL .....	2/23/2021
LGC—Dr. Ehrenstorfer .....	Δ9-Tetrahydrocannabivarin 10,000 mg/L Parent stock in Methanol—NOT FOR SALE.	Boston Round, Amber glass: 14 mL	1/19/2021
LGC—Dr. Ehrenstorfer .....	Delta-9-THC 10000 µg/mL in Methanol .....	Amber ampule: 2 mL .....	2/16/2021

**Opportunity for Comment**

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until he may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as he determines appropriate.

**Approved Exempt Chemical Preparations Are Posted on the DEA’s Website**

A list of all current exemptions, including those listed in this order, is available on the DEA’s website at [http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt\\_chemlist.pdf](http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf). The dates of applications of all current exemptions are posted for easy reference.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. 2021–15024 Filed 7–21–21; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Parole Commission**

**Sunshine Act Meeting**

**Record of Vote of Meeting Closure**

(Public Law 94–409) (5 U.S.C. Sec. 552b)

I, Patricia K. Cushwa, Acting Chairman of the United States Parole Commission, was present at a meeting of said Commission, which started at approximately 2:30 p.m., on Tuesday, July 13, 2021, at the U.S. Parole Commission, 90 K Street NE, Third Floor, Washington, DC 20530. The purpose of the meeting was to discuss an original jurisdiction case pursuant to 28 CFR 2.25. and 28 CFR 2.68(i)(1) Two Commissioners were present, constituting a quorum when the vote to close the meeting was submitted.

Public announcement further describing the subject matter of the meeting and certifications of the General Counsel that this meeting may be closed by votes of the Commissioners present were submitted to the Commissioners prior to the conduct of any other business. Upon motion duly made, seconded, and carried, the following Commissioners voted that the meeting be closed: Patricia K. Cushwa and Charles T. Massarone.

*In witness whereof*, I make this official record of the vote taken to close this meeting and authorize this record to be made available to the public.

**Patricia K. Cushwa,**  
Acting Chairman, U.S. Parole Commission.

[FR Doc. 2021–15788 Filed 7–20–21; 4:15 pm]

**BILLING CODE 4410–31–P**

**SECURITIES AND EXCHANGE COMMISSION**

[Investment Company Act Release No. 34333; 812–15219]

**Capital Southwest Corporation, et al.; Notice of Application**

July 16, 2021.

**AGENCY:** Securities and Exchange Commission (“Commission”).

**ACTION:** Notice.

Notice of an application for an order under section 6(c) of the Investment Company Act of 1940 (the “Act”) for an exemption from sections 18(a) and 61(a) of the Act.

**APPLICANTS:** Capital Southwest Corporation (the “Company”), Capital Southwest SBIC I, LP (the “Capital Southwest SBIC”), and Capital Southwest SBIC I GP, LLC (the “SBIC GP”).

**SUMMARY OF THE APPLICATION:** The Company requests an order to permit it to adhere to a modified asset coverage requirement.

**FILING DATES:** The application was filed on April 21, 2021, and amended on July 14, 2021.

**HEARING OR NOTIFICATION OF HEARING:** An order granting the requested relief will be issued unless the Commission orders a hearing. Interested persons may request a hearing by emailing the Commission’s Secretary at [Secretarys-Office@sec.gov](mailto:Secretarys-Office@sec.gov) and serving applicants with a copy of the request by email. Hearing requests should be received by the Commission by 5:30 p.m. on August 10, 2021, and should be accompanied by proof of service on applicants, in the form of an affidavit or, for lawyers, a certificate of service. Pursuant to rule 0–